NUTX Stock Analysis: Buy, Sell, or Hold?
NUTX - Nutex Health Inc. Common Stock
$99.25
0.81 (0.82%)
▲
5d:
+4.63%
30d:
-8.47%
90d:
-39.71%
BUY
HIGH Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 12, 2026
Get Alerted When NUTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: NUTX trading at deep discount. Market pricing in -15.0% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: NUTX trading at deep discount. Market pricing in -15.0% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$194.47
Based on 3.9% avg growth
INTRINSIC VALUE TODAY
$120.75
17.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NUTX is currently trading at $99.25, which is considered fair relative to its 30-day fair value range of $90.61 to $106.80. From a valuation perspective, the stock is trading at a discount (Forward PE: 4.8) compared to its historical average (7.9). Remarkably, the market is currently pricing in an annual earnings decline of 15.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, NUTX is in a downtrend. Immediate support is located at $85.39, while resistance sits at $102.99.
Market Sentiment: NUTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $221.67 (+125.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NUTX is in a downtrend. Immediate support is located at $85.39, while resistance sits at $102.99.
Market Sentiment: NUTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $221.67 (+125.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$90.61 -
$106.80
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 125.2% below Wall St target ($221.67)
Fair Price Analysis
30-Day Fair Range
$90.61 -
$106.80
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$85.39
Resistance Level
$102.99
Current Trend
Downtrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
4.84
Wall Street Target
$221.67
(+125.2%)
Revenue Growth (YoY)
-41.1%
Earnings Growth (YoY)
-86.2%
Profit Margin
8.1%
Valuation Discount vs History
-15.0% cheaper
PE vs Historical
4.8 vs 7.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-15.0%
(market-implied from PE analysis)
1-Year Target
$88.60
(-10%)
2-Year Target
$79.74
(-19%)
3-Year Target
$71.76
(-27%)
3-Yr Target (if PE normalizes)
(PE: 5→8)
$117.08
(+19%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 3.8%)
$507.84
(+416%)
Base:
(SPY PE: 4.8, Growth: 3.8%)
$110.02
(+12%)
Bear:
(PE: 4.1, Growth: 3.8%)
$93.52
(-5%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (8x PE), but valuation improves significantly next year (5x PE) as earnings recover.
Trailing PE: 8.49 | Current EPS (TTM): $10.48
Bull Case
$189.89
(+100%)
Analyst growth 94.0%, PE expands to 9.3
Base Case
$172.63
(+82%)
Market implied 94.0%, PE stable at 8.5
Bear Case
$60.51
(-36%)
Severe decline -20.0%, PE contracts to 7.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 4.8 to 7.9
Stabilization Target:
$160.61
(+63.2%)
PE Expansion Potential:
+63.2%
Share & Embed Analysis
Last updated: April 02, 2026 2:25 PM ET
Data refreshes hourly during market hours. Next update: 3:25 PM
Data refreshes hourly during market hours. Next update: 3:25 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NUTX showing a specific setup today?
Insider Activity (6 Months)
3
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Kelvin Spears
BUY
10 shares
2026-03-17
Pamela W Montgomery
BUY
79 shares
2026-03-13
Jon Christian Bates
BUY
750 shares
2025-11-25
Top Rated Medical Care Facilities Stocks
Top-rated stocks in Medical Care Facilities by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
THC
Tenet Healthcare Corpora… |
STRONG BUY
22 analysts |
$261 | 61 BUY |
|
HCA
HCA Holdings Inc |
BUY
25 analysts |
$543 | 59 HOLD |
|
EHC
Encompass Health Corp |
STRONG BUY
12 analysts |
$143 | 54 HOLD |
|
CMPS
Compass Pathways Plc |
STRONG BUY
11 analysts |
$22 | 49 HOLD |
|
ASTH
Astrana Health Inc |
STRONG BUY
12 analysts |
$36 | 64 BUY |
